Locally recurrent esophageal carcinoma: When is re-resection indicated?

被引:26
作者
Schipper, PH [1 ]
Cassivi, SD [1 ]
Deschamps, C [1 ]
Rice, DC [1 ]
Nichols, FC [1 ]
Allen, MS [1 ]
Pairolero, PC [1 ]
机构
[1] Mayo Clin, Coll Med, Div Gen Thorac Surg, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.athoracsur.2005.03.099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Limited locally recurrent esophageal carcinoma is rare, and little is known regarding effectiveness of re-resection. Methods. Medical records of 27 consecutive patients with locally recurrent esophageal carcinoma who underwent reoperation at our institution between February 1974 and January 2003 were analyzed. Results. The original and recurrent cancer cell types were identical in all patients. Median disease-free interval was 19.4 months (range, 2.5 to 170 months). Recurrence was at the anastomosis in 23 patients (85%), esophageal remnant in 3 (11%), and stomach in 1 (4%). Ten patients had completion gastrectomy and partial esophagectomy, and 9 had resection of the anastomosis. The remaining 8 patients were found intraoperatively to have unresectable disease and underwent biopsy only. Reresection was complete in 15 of the 19 patients resected (79%). Four patients had microscopic cancer at the resection margins. Reconstruction was with colon in 10 patients and esophagogastrostomy in 9. There were 2 deaths (operative mortality, 7%). Complications occurred in 16 patients (59%). Arrhythmia and anastomotic leak were the most common complications and each occurred in 7 patients (26%). Factors favorably associated with survival were disease-free interval greater than 2 years (p <= 0.05) and complete re-resection (p <= 0.02). Two-, three-, and five-year survival for patients completely re-resected was 62%, 44%, and 35%, respectively. Survival for patients who had incomplete re-resections was 18% at 2 years and zero at 3 years. Conclusions. Re-resection of locally recurrent esophageal carcinoma is associated with considerable morbidity. However, long-term survival is possible in patients with a long disease-free interval or a complete re-resection.
引用
收藏
页码:1001 / 1006
页数:6
相关论文
共 34 条
  • [21] MOUSSA ME, 1995, ANN ROY COLL SURG, V77, P364
  • [22] Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy
    Muto, M
    Ohtsu, A
    Miyata, Y
    Shioyama, Y
    Boku, N
    Yoshida, S
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (06) : 270 - 274
  • [23] Radiation therapy for loco-regionally recurrent esophageal cancer after surgery
    Nemoto, K
    Ariga, H
    Kakuto, Y
    Matsushita, H
    Takeda, K
    Takahashi, C
    Takai, Y
    Yamada, S
    Hosoi, Y
    [J]. RADIOTHERAPY AND ONCOLOGY, 2001, 61 (02) : 165 - 168
  • [24] ASYMPTOTICALLY EFFICIENT RANK INVARIANT TEST PROCEDURES
    PETO, R
    PETO, J
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1972, 135 : 185 - &
  • [25] REOPERATION IN RECURRENCE OF CARCINOMA OF ESOPHAGUS, CARDIA AND STOMACH
    PICHLMAYR, R
    BUTTNER, D
    [J]. LANGENBECKS ARCHIV FUR CHIRURGIE, 1976, 342 : 227 - 235
  • [26] COMBINED RADIOCHEMOTHERAPY FOR POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER
    RAOUL, JL
    LEPRISE, E
    MEUNIER, B
    JULIENNE, V
    ETIENNE, PL
    GOSSELIN, M
    LAUNOIS, B
    [J]. GUT, 1995, 37 (02) : 174 - 176
  • [27] Treatment response and prognosis of patients after recurrence of esophageal cancer
    Shimada, H
    Kitabayashi, H
    Nabeya, Y
    Okazumi, S
    Matsubara, H
    Funami, Y
    Miyazawa, Y
    Shiratori, T
    Uno, T
    Itoh, H
    Ochiai, T
    [J]. SURGERY, 2003, 133 (01) : 24 - 31
  • [28] SOBIN LH, 2002, TNM CLASSIFICATION M, P60
  • [29] Curative reoperations for locally recurrent rectal cancer
    Suzuki, K
    Dozois, RR
    Devine, RM
    Nelson, H
    Weaver, AL
    Gunderson, LL
    Ilstrup, DM
    [J]. DISEASES OF THE COLON & RECTUM, 1996, 39 (07) : 730 - 736
  • [30] Gemcitabine and Cisplatin for patients with metastatic or recurrent esophageal carcinoma: A Southwest Oncology Group study
    Urba, SG
    Chansky, K
    vanVeldhuizen, PJ
    Pluenneke, RE
    Benedetti, JK
    Macdonald, JS
    Abbruzzese, JL
    [J]. INVESTIGATIONAL NEW DRUGS, 2004, 22 (01) : 91 - 97